USE AND RESEARCH-ENTHEOGENS
SB2184 creates the Compassionate Use and Research of Entheogens Act, a comprehensive framework to regulate psilocybin and related entheogens in Illinois. The bill would remove psilocybin and psilocin from Schedule I of the Illinois Controlled Substances Act and establish a state licensing system for psilocybin product manufacturers, testing laboratories, service centers, and facilitators. It also creates an Illinois Psilocybin Advisory Board within the Department of Financial and Professional Regulation to advise agencies during a multi-year program development period before licenses are issued.
The bill sets out detailed rules for adult access, limiting participation to people 21 and older and requiring a referral from a licensed health professional before a client may receive psilocybin services. It requires preparation, administration, post-administration evaluation, and integration sessions, along with client intake forms, transportation plans, safety plans, confidentiality protections, labeling and packaging standards, testing requirements, and background checks. The bill also creates the Psilocybin Control and Regulation Fund and the Illinois Psilocybin Fund, authorizes civil and criminal penalties for violations, and preempts local governments from creating their own licensing or tax systems, while still allowing reasonable zoning rules.
SB2184 would also impose a 15% tax on psilocybin purchases beginning January 1, 2026, with revenue directed to state funds used for regulation and administration. Related amendments would update the Illinois Vehicle Code to treat driving after unlawful psilocybin use as a DUI-related offense, amend the Freedom of Information Act to exempt certain psilocybin-related records, and assign tax disputes under the new act to the Illinois Independent Tax Tribunal. The bill further includes provisions on age verification, recordkeeping, inspections, and enforcement authority for the Department of Agriculture, the Department of Financial and Professional Regulation, the Illinois State Police, and the Department of Revenue.
Because there were no committee transcripts or recorded votes provided, there is no documented legislative debate or recorded sentiment in the available materials. Based on the bill text alone, the measure appears to be framed as a public-health and harm-reduction proposal, with extensive regulatory safeguards and equity provisions. At the same time, its scope is broad and would significantly change Illinois drug, tax, licensing, and privacy law, which suggests it could draw scrutiny over public safety, implementation, and the legalization of a currently controlled substance.
The bill would substantially revise Illinois law by decriminalizing regulated psilocybin activity for licensed participants, creating new licensing and oversight structures, and carving psilocybin and psilocin out of the state’s Schedule I controlled substances list. It would also add new tax provisions, fund structures, confidentiality rules, enforcement powers, and vehicle-code restrictions, while limiting local government authority over licensing and taxation. Affected parties would include manufacturers, laboratories, service centers, facilitators, clients, health professionals issuing referrals, and state agencies responsible for agriculture, professional regulation, revenue, and policing.
No committee discussion or vote history was provided, so there is no recorded legislative sentiment to summarize from hearings or roll calls. From the bill text, the sponsor’s framing is strongly supportive of regulated therapeutic access, harm reduction, and research, with repeated references to public health, equity, and safety. The absence of recorded opposition in the supplied materials means any controversy is inferred from the bill’s subject matter rather than documented debate.
The main points of contention likely concern the legalization and regulation of psilocybin, the requirement that adults obtain a referral before use, the 15% tax, and the bill’s preemption of home rule authority over licensing and local taxation. Other potentially disputed issues include the breadth of confidentiality exemptions, the extent of state agency enforcement powers, the DUI-related amendment covering psilocybin metabolites, and whether the proposed framework is sufficiently protective of public safety while still enabling access. The bill text also signals sensitivity around Indigenous use of peyote and the exclusion of peyote from the act, which may be relevant to stakeholders focused on cultural and religious protections.